pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

48 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1853Endpoints1439Fierce Biotech754BioSpace744BioPharma Dive544raps249onclive165fda recalls
therapy area
allOncology12820Rare Disease3324Immunology2980Cardiology2845Hematology2281Pulmonology2229Vaccines
  • Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billion
    Johnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…
    Endpoints · 1d agoDealPositive↗ source
  • ALDI recalls Priano protein tortelloni over possible Clostridium botulinum contamination
    ALDI of Batavia, Illinois announced on November 16, 2026 that it is recalling its Priano Protein Carbonara Tortelloni and Priano Protein Herb & Cheese Tortelloni sold at select stores in Alabama, G…
    fda recalls · 1d agoRegulatoryNegative↗ source
← prev
page 1 of 2
next →
118
fda medwatch114
globenewswire health73
fda press61
1844
Psychiatry & CNS1229
Ophthalmology1128
Endocrinology & Metabolism805
Pain789
Nephrology782
  • FDA orders label warnings for GLP-1 drugs over rare eye-loss risk
    The U.S. Food and Drug Administration has issued a safety communication that requires all glucagon-like peptide-1 receptor agonist (GLP-1 RA) products to add new warnings to their labeling. The ad…
    fda medwatch · 9d agoRegulatoryNegative↗ source
  • FDA requires GLP-1 drug labels to include warning about rare eye disease
    The FDA has issued a directive to manufacturers of GLP-1 therapies, instructing them to revise product labeling. The label change must highlight an increased risk of a rare ocular condition that c…
    Endpoints · 8d agoRegulatoryNeutral↗ source
  • New treatments for preeclampsia move closer to patients
    Emily Chaddock’s experience highlights the danger of severe preeclampsia, a pregnancy complication that can threaten both mother and baby. At 27 weeks she developed the condition, leading to a rapi…
    Endpoints · 12d agoPositive↗ source
  • Minghui Pharma sells Japanese rights to its Phase 3 thyroid eye disease drug for $110 million upfront
    Minghui Pharmaceutical, a Shanghai‑based biotech, has agreed to transfer the Japanese commercial rights for its late‑stage thyroid eye disease candidate to a specialty pharmaceutical company. The…
    Endpoints · 14d agoDealPositive↗ source
  • Spyre Therapeutics reports SPY072 fails psoriatic arthritis trial as Ideaya halts eye cancer study
    Spyre Therapeutics announced that its long‑acting anti‑TL1A candidate, SPY072, did not meet the primary endpoints in a psoriatic arthritis trial. The result adds to recent setbacks for Spyre in ot…
    Endpoints · 13d agoNegative readoutNegative↗ source
  • Haifa Smoked Fish recalls 560 lbs of cold-smoked sprats over possible Clostridium botulinum contamination
    Haifa Smoked Fish of Queens, NY announced a recall of about 560 pounds of its cold-smoked sprats after testing indicated possible contamination with Clostridium botulinum, a bacterium that can caus…
    fda recalls · 21d agoRegulatoryNegative↗ source
  • Aspen Neuroscience and Bambusa Therapeutics each aim for $135 million IPOs
    Aspen Neuroscience announced plans to raise about $135 million through an initial public offering, proposing to sell roughly 9.38 million shares. Bambusa Therapeutics also filed for an IPO targeti…
    Endpoints · 22d agoDealNeutral↗ source
  • Alcon buys Neurotech for $550 million upfront
    Alcon, the Swiss eye‑care company, announced it has completed the acquisition of Neurotech Pharmaceuticals. The transaction includes an upfront cash payment of $550 million, with the possibility o…
    Endpoints · 27d agoDealNeutral↗ source
  • Astellas teams up with Boston miniprotein startup to explore AI-designed tiny proteins
    Astellas Pharma announced a partnership with a Boston-based startup that specializes in miniproteins, small engineered proteins that can serve as therapeutic agents. The startup leverages artifici…
    Endpoints · 28d agoDealPositive↗ source
  • EyePoint's Phase 3 trial fails, prompting 53% staff cuts; Lilly signs China drug delivery partnership
    EyePoint, a Watertown, Massachusetts biotech, reported that its experimental therapy did not meet primary endpoints in a Phase 3 study, marking a setback for the company. Following the trial failu…
    Endpoints · 29d agoNegative readoutNegative↗ source
  • Rudy Tanzi says he may be nearing a cheap, safe Alzheimer’s prevention pill
    Rudolph Tanzi has spent decades pursuing a way to stop Alzheimer’s disease before it starts. As a leading researcher, he has long spoken about the need for a simple, widely accessible solution. T…
    Endpoints · 1mo agoPositive↗ source
  • Merck's diabetic eye-disease drug hits primary goal but faces commercial doubts
    Merck announced results from a pivotal trial of its ophthalmology candidate remigromig, aimed at treating diabetic macular edema. The study achieved its primary endpoint, demonstrating that remigr…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • Bausch + Lomb CEO Brent Saunders abruptly departs after failed multibillion-dollar sale
    Brent Saunders, known as a leading dealmaker and one of the highest-paid executives in biopharma, has left his role as chief executive of Bausch + Lomb. His departure ends a second stint as CEO of…
    Endpoints · 1mo agoNegative↗ source
  • AI startup Chai Discovery inks GSK deal to develop biologics using artificial intelligence
    Chai Discovery, an artificial‑intelligence focused biotech, has signed a collaboration agreement with GlaxoSmithKline to create biologic medicines using its AI platform. The partnership will lever…
    Endpoints · 1mo agoDealPositive↗ source
  • Bayer outlines $2.2 billion Ohio plant that will add roughly 600 jobs
    Bayer announced its plan for a new manufacturing complex in New Albany, Ohio, with an investment of about $2.2 billion. The facility is expected to create roughly 600 new jobs in the region, suppo…
    Endpoints · 1mo agoPositive↗ source
  • Aviceda Therapeutics to wind down after Phase 2 failure in geographic atrophy program
    Aviceda Therapeutics, a biotech focused on geographic atrophy, announced it is winding down operations. The decision follows a Phase 2 trial that did not meet its endpoints, halting plans to move…
    Endpoints · 1mo agoNegative↗ source
  • Ascletis pursues oral IL-17A inhibitor for psoriasis as Invivyd readies COVID-19 filing
    Ascletis, a biotech listed in Hong Kong, is developing a small‑molecule IL-17A inhibitor in pill form to treat psoriasis. The company aims to challenge the current injectable therapies that target…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Kodiak Sciences reports Phase 3 success for Zenkuda, matching Eylea in wet AMD
    Kodiak Sciences announced that its experimental therapy Zenkuda achieved comparable efficacy to the market‑leading anti‑VEGF drug Eylea in a late‑stage trial for wet age‑related macular degeneratio…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Merck's $1.3B EyeBio investment yields first ophthalmology success
    Merck's strategic move to re-enter ophthalmology has begun to show results after its 2024 acquisition of EyeBio. The company committed $1.3 billion upfront for EyeBio, aiming to broaden its pipeli…
    Endpoints · 1mo agoDealPositive↗ source
  • Beacon Therapeutics reports successful gene-therapy trial for rare X-linked retinitis pigmentosa
    Beacon Therapeutics announced that its gene-therapy candidate for X-linked retinitis pigmentosa (XLRP) achieved its primary endpoint in a pivotal trial. The result marks a breakthrough for the rar…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Novo outlines diversification strategy with new pipeline assets and bolt-on deals
    Novo Pharmaceuticals' chief executive Maziar Mike Doustdar used the company's recent capital-markets day in London to lay out a diversification plan. He said the rebranded firm will focus on expand…
    Endpoints · 1mo agoDealPositive↗ source
  • Sling Therapeutics raises $123M to fund Phase 3 trial of former Astellas cancer drug for thyroid eye disease
    Investors have committed $123 million to Sling Therapeutics, a small Michigan biotech focused on eye‑disease treatments. The funding will support a Phase 3 clinical trial of a drug originally deve…
    Endpoints · 2mo agoDealPositive↗ source
  • Fi recalls dog supplements over possible Salmonella contamination
    Fi, a New York-based company, announced a recall of its dog supplement products due to potential Salmonella contamination linked to an ingredient supplied to its manufacturer. The manufacturer has…
    fda recalls · 2mo agoCRLNegative↗ source